New
phase II facts introduced for the very first time at the 2012 European
Respiratory Society (ERS) congress demonstrate that combining tiotropium along
with olodaterol significantly enhanced lung function (FEV1) over 24 hours in
COPD affected individuals in comparison with olodaterol alone.
Significant
enhancements were spotted for all combinations of doses examined in comparison
to the respective olodaterol monotherapies. Both therapies were applied by
using the patient-preferred Respimat Soft MistTM Inhaler (SMI) device.
After
4 weeks of therapy, the mixture of tiotropium and olodaterol provided a mean
lung function development when compared to pre-treatment baseline of up to 342
ml during the first 6 hours (FEV1 AUC0-6) and enhancements in trough FEV1 of up
to 166 ml.
In
comparison with olodaterol monotherapy, the mixture of tiotropium and
olodaterol further elevated lung functionality by up to 144 ml.
